Low-dose liposomal amphotericin B in refractory Indian visceral leishmaniasis: A multicenter study

American Journal of Tropical Medicine and Hygiene

Volumn 66, Issue 2, 2002, Pages 143-146

  Sundar, S ^a   Jha, T K ^a   Thakur, C P ^a   Mishra, M ^a   Singh, V P ^a   Buffels, R ^a  

^a NONE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; ANTIMONY;

ADOLESCENT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; DRUG INDICATION; FEMALE; FEVER; FOLLOW UP; HUMAN; INDIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROTOXICITY; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RIGOR; SCHOOL CHILD; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS;

NASO HEXACANTHUS; PROTOZOA;

EID: 0036314758     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2002.66.143     Document Type: Article

References (17)

1. Epidemiology of visceral leishmaniasis in India
2. Response to interferon-γ plus pentavalent antimony in Indian visceral leishmaniasis
3. Do the diminishing efficacy and increasing toxicity of sodium stibogluconate in the treatment of visceral leishmaniasis in Bihar, India, justify its continued use as a first-line drug? An observational study of 80 cases
4. Changing response to diamidine compounds in cases of kala-azar unresponsive to antimonial
5. Cure of 72 antimony and pentamidine resistant kalaazar cases with amphotericin B
6. Use of amphotericin B in drug-resistant cases of visceral leishmaniasis in north Bihar
7. Cure of antimony-unresponsive Indian visceral leishmaniasis with amphotericin B lipid complex
8. Short-course, low dose amphotericin B lipid complex therapy for visceral leishmaniasis unresponsive to antimony
9. Amphotericin B lipid complex in the management of antimony unresponsive Indian visceral leishmaniasis
10. Treatment of antimony-unresponsive Indian visceral leishmaniasis with ultra-short courses of amphotericin B lipid complex
11. Comparison of three treatment regimens with liposomal amphotericin B (AmBisome) for visceral leishmaniasis in India: A randomized dose-finding study
12. Treatment of Brazilian kala-azar with a short course of Amphocil (amphotericin B cholesterol dispersion)
13. Liposomal amphotericin B (AmBisome) in Mediterranean visceral leishmaniasis: A multi-centre trial
14. Liposomal amphotericin B (AmBisome) in the treatment of complicated kala-azar under field conditions
15. Amphotericin versus pentamidine in antimony-unresponsive kala-azar
16. U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis
17. Efficacy and safety of liposomal amphotericin B (AmBisome) for visceral leishmaniasis in endemic developing countries